Vir Biotechnology Stock News

The immunology specialist says it can help combat omicron.

Gainers Nxt-ID, Inc. (NASDAQ: NXTD ) shares gained 28.9% to $3.21 after the company said it was awarded U.S. General Services Administration contract to distribute personal emergency response systems to Federal, State and Local government purchasers. Biofrontera Inc. (NASDAQ: BFRI ) shares climbed 27.6% to $7.02 after Benchmark initiated coverage on the stock with a Buy rating and announced a $11 price target. CMC Materials, Inc. (NASDAQ: CCMP ) surged 25.9% to $183.74 after the company announced it will be acquired by Entegris for $6.5 billion in cash and stock. Insignia Systems, Inc. (NASDAQ: ISIG ) surged 21.2% to $20.18. Gemini Therapeutics, Inc. (NASDAQ: GMTX ) gained 21% to $2.94 after HC Wainwright & Co initiated coverage on the stock with a Buy rating and a $20 price target. mCloud Technologies Corp. (NASDAQ: MCLD ) jumped 17.2% to $4.6405 after the company signed a cloud agreement with Virtual Vision to host AssetCare customers in Saudi Arabia. Vir Biotechnology, Inc. (NASDAQ: VIR ) gained 15.2% to $53.03 after the company announced new preclinical data demonstrating the impact of the significant antigenic shift of the new SARS-CoV-2 Omicron variant.

Vir Biotechnology Inc (NASDAQ: VIR) announced new preclinical data, published to the preprint server  bioRxiv , demonstrating the impact of the significant antigenic shift of the new COVID-19 omicr

Data demonstrate sotrovimab, developed by Vir in conjunction with GlaxoSmithKline, continues to retain in vitro neutralizing activity against all tested variants of concern, including Omicron SAN FRANCISCO , Dec. 14, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc.

NEW YORK , Dec. 14, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VIR, PFE, AAPL, TSLA, and AMC. Full story available on Benzinga.com

Wall Street brokerages predict that Vir Biotechnology, Inc. (NASDAQ:VIR) will report sales of $124.06 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Vir Biotechnologys earnings, with the lowest sales estimate coming in at $123.90 million and the highest estimate coming in at $124.21 million. Vir Biotechnology [] The post Vir Biotechnology, Inc. (NASDAQ:VIR) Expected to Announce Quarterly Sales of $124.06 Million appeared first on ETF Daily News .

Trial to evaluate antigen suppression combined with immunomodulation as a functional cure regimen for chronic HBV SAN FRANCISCO, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ: VIR ) today announced that the first patient has been dosed in a Phase 2 clinical trial evaluating novel therapeutic combinations for the treatment of chronic hepatitis B virus (HBV) infection. The multi-arm trial, which is being conducted in collaboration with Gilead Sciences, Inc., is assessing various combinations of VIR-2218, Vir''s investigational small interfering ribonucleic acid (siRNA) that mediates RNA interference (RNAi); selgantolimod (GS-9688), Gilead Sciences'' investigational TLR-8 agonist; and nivolumab, an approved PD-1 inhibitor, in both nucleos(t)ide (NUC)-suppressed patients and viremic patients. Patients with HBV treatment experience also may receive tenofovir alafenamide fumarate (TAF). "For the majority of patients with chronic HBV, a functional cure will likely require a sustained reduction in hepatitis B surface antigen and restoration of the immune response," said Carey Hwang, MD, PhD, senior vice president, clinical research, head of chronic infection for Vir Biotechnology. "We believe the combination of VIR-2218 and two immunomodulatory agents has the potential to improve the HBV-specific immune response and possibly achieve a functional cure.

Vir Biotechnology (NASDAQ:VIR)s stock had its buy rating reaffirmed by equities research analysts at HC Wainwright in a research note issued to investors on Wednesday, TipRanks reports. They currently have a $199.00 price objective on the stock. HC Wainwrights price objective would indicate a potential upside of 370.00% from the stocks previous close. VIR has []

Vir Biotechnology, Inc. (NASDAQ:VIR) dropped 4.6% on Wednesday . The company traded as low as $40.80 and last traded at $41.00. Approximately 1,423 shares changed hands during trading, a decline of 100% from the average daily volume of 1,224,537 shares. The stock had previously closed at $42.98. VIR has been the subject of a number []

The stock price of Vir Biotechnology Inc (NASDAQ: VIR) increased by over 11% today. This is why it happened.

The brand name XEVUDY was developed in partnership with Brand Institute, the global leader in pharmaceutical and healthcare-related name development MIAMI, Dec. 7, 2021 /PRNewswire/ -- Brand Insti

GlaxoSmithKline and Vir Biotechnology reported their Covid-19 antibody treatment retained effectiveness against the Omicron variant in laboratory studies.

Yahoo Finance's Anjalee Khemlani details government officials' changes to international travel into the U.S. and the reported effectiveness of GSK-Vir's proposed drug against Omicron variant. Don't Mi

GSK Claims New Anitbody Drug Is Still Effective Against Omicron GSK has just released more data on its new COVID antibody-drug and - surprise, surprise - the company and its American partner claim there is no evidence that the drug is less effective against the omicron variant. GlaxoSmithKline and Vir Biotechnology released the updated preclinical data early Tuesday in the US. The data showed that the pair''s investigational monoclonal antibody sotrovimab continues to show "in vitro activity" against the full known omicron spike protein, according to a statement. This includes 37 identified mutations of the spike protein. Although none of this data has been published in a peer-reviewed medical journal. The data builds on initial preclinical data released last week showing GSK''s antibody drug retains in vitro activity against key individual mutations of the omicron variant. But Tuesday''s data is even more encouraging. "Given the less than three-fold neutralization shift demonstrated in the pre-clinical pseudo- virus assay, which falls below the FDA authorized fact sheet guidance of less than a 5-fold change, we are confident that sotrovimab will continue to provide significant benefit for the early treatment of patients hoping to avoid the most severe consequences of COVID-19," said Vir CEO George Scangos.

GlaxoSmithKline plc confirmed on Tuesday that its COVID-19 therapy jointly developed with Vir Biotechnology is effective against the Omicron coronavirus mutation. "Sotrovimab is the first monocl